Tryptophan for Impaired AhR Signaling in Celiac Disease
Key facts
- Where
- Hamilton, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05576038, who can take part
Where in Canada
- McMaster UniversityHamilton, CanadaContact: David ArmstrongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- McMaster University
- Trial code
- NCT05576038
- Record updated
- 10 January 2025
- Original description
This is a prospective, randomized, double-blind, placebo-controlled exploratory trial to evaluate the effect of L-tryptophan supplementation on celiac-related symptoms in individuals who have biopsy-confirmed celiac disease (CeD) and symptoms non-responsive to a gluten-free diet (GFD). Fifty participants, aged 18 to 75 years, who self-report persistent CeD-related symptoms despite taking a GFD for more than 1 year and who score > 40 on the Celiac Symptom Index (CSI) will be randomized to receive L-tryptophan or placebo for 3 weeks.Read full original descriptionShow less
Restoration of Impaired Microbiota-mediated Aryl Hydrocarbon Receptor Signaling in Celiac Disease by Oral Tryptophan Supplementation: an Exploratory, Pilot Trial
This is a prospective, randomized, double-blind, placebo-controlled exploratory trial to evaluate the effect of L-tryptophan supplementation on celiac-related symptoms in individuals who have biopsy-confirmed celiac disease (CeD) and symptoms non-responsive to a gluten-free diet (GFD). Fifty participants, aged 18 to 75 years, who self-report persistent CeD-related symptoms despite taking a GFD for more than 1 year and who score > 40 on the Celiac Symptom Index (CSI) will be randomized to receive L-tryptophan or placebo for 3 weeks.
Inclusion: 18 and 75 years of age; Celiac disease (CeD) diagnosis: Individuals with histological and serological evidence of CeD serology (positive biopsy and anti-tTG IgA); Persistent CeD related symptoms (>40 on the Celiac Symptom Index) despite >1 year of a gluten free diet (GFD).
Exclusion: Acid anti-secretory and antacid medications; Concurrent organic GI pathology other than benign polyps, haemorrhoids, lipomas, Helicobacter pylori infection, diverticulosis and melanosis coli; Chronic treatment with high dose opioids; Alcohol or drug abuse; Use of lithium and monoamine oxidase inhibitors (MAOIs); Current organic gastrointestinal or other autoimmune diseases, such as inflammatory bowel disease or diabetes mellitus (type 1); History of bariatric surgery, fundoplication or gastrectomy (partial or complete); Connective tissue disease; Allergy or sensitivity to any component of the study medication or placebo; Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection; Antibiotics, antibacterial agents or probiotics, currently, or within the last 8 weeks; Lactose and/or fructose intolerance; Participation in another dietary treatment study within the last 4 weeks.